A Study of Bevacizumab in Previously Untreated Extensive-Stage Small Cell Lung Cancer (SALUTE)

Inclusion Criteria: * Histologically or cytologically documented small cell carcinoma of the bronchus, classified as extensive-stage disease * Measurable disease or lesions * Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2 Exclusion Criteria: * Life expectancy of \< 12 weeks * Current, recent, or planned participation in another experimental drug study * Ongoing or active infection * Active malignancy other than SCLC or superficial basal/squamous cell carcinoma within the previous 5 years * Prior systemic therapy, radiation therapy, or surgery for SCLC * Inadequate bone marrow function, renal function, or hepatic function * Serum sodium of \< 120 mg/dL * Inadequately controlled hypertension * History of hypertensive crisis or hypertensive encephalopathy * New York Heart Association Class II or greater congestive heart failure * History of myocardial infarction or unstable angina within 6 months prior to study enrollment * History of stroke or transient ischemic attack within 6 months prior to study enrollment * Known central nervous system disease, except for brain metastases treated with whole-brain radiotherapy * Significant vascular disease or recent peripheral arterial thrombosis within 6 months prior to study enrollment * History of hemoptysis within 4 weeks prior to study enrollment * Evidence of bleeding diathesis or coagulopathy in the absence of therapeutic anticoagulation * Major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to study enrollment or anticipation of a need for a major surgical procedure during the course of the study * Core biopsy or other minor surgical procedure, including placement of a vascular access device, within 7 days prior to Day 1 * History of abdominal fistula or gastrointestinal perforation within 6 months prior to study enrollment * Serious, non-healing wound, active ulcer, or untreated bone fracture * Known hypersensitivity to any component of bevacizumab * Pregnant (positive pregnancy test) or lactating